Important Notice for REGENXBIO Investors on Securities Class Action Deadline by Faruqi & Faruqi

Important Update for REGENXBIO Shareholders

In a significant development for investors in REGENXBIO Inc. (NASDAQ: RGNX), the national law firm Faruqi & Faruqi, LLP is urging those who acquired securities in the company from February 9, 2022, to January 27, 2026, to take action. With a deadline of April 14, 2026, looming for filing a lead plaintiff motion in a federal securities class action lawsuit, time is of the essence for affected shareholders to assert their rights.

Faruqi & Faruqi is renowned for its expertise in securities litigation and has successfully recovered substantial financial settlements for investors since its establishment in 1995. The firm specializes in protecting the rights of shareholders and encourages anyone who suffered losses related to REGENXBIO's stock to reach out. This action stems from allegations that the company, along with its executives, may have violated federal securities laws by issuing misleading statements regarding the safety and efficacy of their product, RGX-111, particularly in relation to a pivotal clinical trial.

On January 28, 2026, REGENXBIO publicly announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on RGX-111 due to safety concerns linked to a case of neoplasm observed during the trial. This announcement had an immediate adverse effect on the stock, resulting in a drop of $2.40 per share, or nearly 18%, marking its value at $11.01 at closing. Investors are now faced with the possibility that these disclosures were not communicated in a timely or effective manner, leading them to incur significant losses.

The lead plaintiff in a class action lawsuit represents the interests of the entire class and is tasked with overseeing the litigation. This individual is often the person or entity that has the largest financial stake in the case. Investors can opt to submit a motion to serve as lead plaintiff through their legal representation or may choose to remain passive participants. Importantly, one's eligibility for recovering any financial restitution is not dependent on the decision to step forward as a lead plaintiff.

In light of these developments, Faruqi & Faruqi is also seeking information from anyone who may have insights into REGENXBIO’s practices, including past employees or whistleblowers, to aid in building a stronger case. Stakeholders are encouraged to connect directly with attorney Josh Wilson at the firm for guidance on their individual situations.

Just as critical as understanding the legal process is the actual act of engagement. Those who believe they have been affected should not delay in reaching out, as the window for recourse is limited. To get more detailed information regarding the class action or to discuss legal options, interested parties should visit Faruqi & Faruqi’s website or call directly for assistance.

This reminder underscores the importance of vigilance and timely action within the investment community. For those affected by the fluctuations in REGENXBIO’s stock driven by corporate decisions and communications, the period leading up to April 14, 2026, represents a crucial time for reassessing rights and taking necessary steps to protect financial interests.